Our latest news for ‘NAFLD’

We are proud to be leading the way in providing more patient-centric solutions for people with liver disease that helps them and their physician make informed decisions about their care.

Read our latest news to find out more about how we are helping to improve the understanding of liver disease.

New non-invasive MRI biomarker for liver disease could cut costs for drug trials Posted: September 22, 2020

First European guidance on the use of multiparametric MRI in fatty liver disease Posted: September 4, 2020

LiverMultiScan Liver Disease NAFLD NASH

Multiparametric MRI: bridging the diagnostic gap for liver disease Posted: August 7, 2020

Multiparametric MRI Liver Disease NAFLD NASH

Quantitative MRI; a game changer for identifying the chronic liver disease patients most at risk of poor clinical outcomes Posted: August 4, 2020

LiverMultiScan Liver Disease NAFLD NASH

The link between type 2 diabetes and liver disease: can screening for NAFLD reduce liver-related mortality? Posted: July 23, 2020

NAFLD Type 2 Diabetes NASH

Video: An FDA-Cleared Non-Invasive Test for Liver Disease Posted: April 1, 2020

LiverMultiScan liver health liver disease high risk group immunosuppressed liver transplant liver cancer liver patients Fatty Liver Disease NAFLD MRI Liver Disease

[Press Release] Large population imaging study reveals utility of LiverMultiScan’s corrected T1 measure as potential biomarker for liver health in metabolic diseases Posted: July 27, 2018

Liver Disease Biomarker liverhealth NAFLD NASH ClinicalTrials

Multiparametric liver MRI could refine the way we currently approach testing of therapeutic candidates in preclinical models Posted: July 3, 2018

Liver Disease NAFLD NASH LiverMultiScan

BBC presents LiverMultiScan on the ‘The Big Crash Diet’ Posted: May 30, 2018

LiverMultiScan NAFLD NASH Liver Disease BBC